Drug Trial Radar · NCT06597565
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
43
Planned (sponsor's estimate)
Start
Sep 25, 2024
Primary completion
Aug 23, 2028
Study completion Aug 23, 2028
Sponsor
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Acrivon Therapeutics
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the activity and safety of ACR-368 (prexasertib) in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Participants will receive the study drugs ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week cycles and will continue on treatment unless the disease deteriorates.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
GemcitabineDrug
Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368.
ACR-368Drug
ACR-368 is an experimental drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate: Cohort ATime frame: Up to 24 Months
- Overall Response Rate: Cohort BTime frame: Up to 24 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.